R

REGENXBIO
D

RGNX

5.95000
USD
-0.37
(-5.85%)
Post Trading
حجم التداول
11,185
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
298,012,521
أصول ذات صلة
C
CRSP
-0.320
(-1.00%)
31.790 USD
E
EDIT
-0.05400
(-5.24%)
0.97600 USD
N
NTLA
-0.29000
(-4.41%)
6.29000 USD
S
SGMO
-0.03080
(-4.73%)
0.62000 USD
المزيد
الأخبار المقالات

العنوان: REGENXBIO

القطاع: Healthcare
الصناعة: Biotechnology
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.